Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial was written by Roostaei Firozabad, Amirreza;Meybodi, Zohreh Akhoundi;Mousavinasab, Seyed Ruhollah;Sahebnasagh, Adeleh;Jelodar, Mohsen Gholinataj;Karimzadeh, Iman;Habtemariam, Solomon;Saghafi, Fatemeh. And the article was included in BMC Infectious Diseases in 2021.HPLC of Formula: 14769-73-4 This article mentions the following:
Abstract: Background: Levamisole has shown clin. benefits in the management of COVID-19 via its immunomodulatory effect. However, the exact role of Levamisole effect in clin. status of COVID-19 patients is unknown. We aimed to evaluate the efficacy of Levamisole on clin. status of patients with COVID-19 during their course of the disease. Methods: This prospective, double-blind, randomized controlled clin. trial was performed in adult patients with mild to moderate COVID-19 (room-air oxygen saturation > 94%) from late Apr. 2020 to mid-August 2020. Patients were randomly assigned to receive a 3-day course of Levamisole or placebo in combination with routine standard of care. Results: With 25 patients in each arm, 50 patients with COVID-19 were enrolled in the study. Most of the study participants were men (60%). On days 3 and 14, patients in Levamisole group had significantly better cough status distribution when compared to the placebo group (P-value = 0.034 and 0.005, resp.). Moreover, there was significant differences between the two groups in dyspnea at follow-up intervals of 7 (P-value = 0.015) and 14 (P-value = 0.010) days after receiving the interventions. However, no significant difference in fever status was observed on days 1, 3, 7, and 14 in both groups (P-value > 0.05). Conclusion: The results of the current study suggest that Levamisole may improve most of clin. status of patients with COVID-19. The patients receiving Levamisole had significantly better chance of clin. status including cough and dyspnea on day 14 when compared to the placebo. However, the effect-size of this finding has uncertain clin. importance. Trial registration: The trial was registered as IRCT20190810044500N7 (19/09/2020). In the experiment, the researchers used many compounds, for example, (S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole (cas: 14769-73-4HPLC of Formula: 14769-73-4).
(S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole (cas: 14769-73-4) belongs to thiazole derivatives. The higher aromaticity of thiazole is due to delocalization of a lone pair of sulfur electrons across the ring, which is evidenced by chemical shifts of ring hydrogen at δ 7.27 and 8.77 ppm (C2 and C4), indicating diamagnetic ring current. Various laboratory methods exist for the organic synthesis of thiazoles. Prominent is the Hantzsch thiazole synthesis is a reaction between haloketones and thioamides.HPLC of Formula: 14769-73-4
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica